A Pilot Study to Evaluate the Safety and Activities of EW02 in Reducing Neutropenia Caused by Chemotherapy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00555516|
Recruitment Status : Unknown
Verified November 2007 by Tri-Service General Hospital.
Recruitment status was: Recruiting
First Posted : November 8, 2007
Last Update Posted : November 8, 2007
EW02 is a polysaccharide-enriched crude extract from black soybean (BS). BS has been used extensively by the Chinese as food or traditional Chinese medicine for hundreds of years. It has been used as monotherapy to treat Diabetes, menorrhagia and leukorrhea. In combination with others, BS has been used to treat chemotherapy-induced leukopenia on more than 300 pts. The daily doses were 15g bid to 50g tid for 21 days. Side effects were generally mild, including epigastric discomfort, numbness, insomnia, and dry mouth. Recently BS was found to promote myelopoiesis and inhibit tumor growth through immunomodulation. In vitro assays showed BS-PS can stimulate production of cytokines and increase blood progenitors. In vivo studies also demonstrated that BS-PS can reduce neutropenia in mice received 5-FU by stimulating myeloid colony formation. We hypothesize that EW02 can reduce neutropenia in cancer patients who receive chemotherapy without side effects.
|Condition or disease||Intervention/treatment||Phase|
|Breast Cancer Chemotherapy Neutropenia||Other: EW02||Phase 1 Phase 2|
This is a single-center, double-blind, placebo-controlled parallel, pilot study of oral EW02 in combination with chemotherapy, versus placebo in combination with chemotherapy in breast cancer patients as the primary phase (Cycle 1). The chemotherapy regimen is restricted to one of the following regimens: Doxorubicin + Cyclophosphamide (AC), or Doxorubicin+ Cyclophosphamide+5-FU (CAF) under standardized dosage. The WBC recovery time is similar between these two chemotherapy regimens due to the facts that doxorubicin and cyclophosphamide are overlapped and their dose in CAF is reduced. The principle investigator has clinical experiences that the neutropenia nadir and severity caused by these two regimens are almost the same. Nevertheless, pre-stratification by chemotherapy regimen (stratum AC versus stratum CAF) at randomization will be implemented so that equal sample size of two study products will be allocated under each stratum. It will involve 60 outpatients for breast cancer, who have previously demonstrated a fall unto 1,000 to 3,000/mm3 in WBC count, or unto 500 to 1,500/mm3 in ANC count, on Day 8 or Day 15, whilst on Cycle 1.
The second phase (Cycle 2): EW02 at 700mg tid daily versus placebo group are given at the beginning of Cycle 2 for 15 consecutive days. 60 subjects will be randomized 2:1 to two groups in pre-stratified permuted blocks of six with four subjects assigned to Group 1 (EW02) while two subjects assigned to Group 2 (Placebo). Group 1 will receive EW02 for 15 consecutive days during the second cycle and Group 2 will receive 15 consecutive days of Placebo.
The extension phase (Cycle 3): is designed to collect additional safety data and to ensure all the participants will have the opportunity to receive study drug. Thus, both groups will receive EW02 at 700mg tid/day for 15 consecutive days.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Primary Purpose:||Supportive Care|
|Official Title:||A Phase I/II Double-Blind, Randomized, Placebo-Control Pilot Study to Evaluate the Safety and Pharmacodynamic Activities of EW02 in Reducing Neutropenia Caused by Breast Cancer Chemotherapy|
|Study Start Date :||November 2007|
|Estimated Study Completion Date :||June 2009|
Active Comparator: 1
Placebo Comparator: 2
- % change from Visit 5 (C2, Day 1) to Visit 7 (C2, Day 15) in WBC, [ Time Frame: % change from Visit 5 (C2, Day 1) to Visit 7 (C2, Day 15) in WBC, ]
- % change from Visit 5 (C2, Day 1) to Visit 7 (C2, Day 15) in ANC [ Time Frame: % change from Visit 5 (C2, Day 1) to Visit 7 (C2, Day 15) in WBC ]
- QOL analysis using EORTC questionnaires ndex scores [ Time Frame: % change from Visit 5 (C2, Day 1) to Visit 7 (C2, Day 15) in QOL index scores ]
- Inter-group comparison of Quality of Life survey collected for Cycle 2 [ Time Frame: % change from Visit 5 (C2, Day 1) to Visit 7 (C2, Day 15) in QOL index scores ]
- Within group analysis (based on "same person comparison"), on the change of WBC/ANC and QOL index scores [ Time Frame: % change from Visit 5 (C2, Day 1) to Visit 7 (C2, Day 15) in QOL index scores ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00555516
|Contact: Tsu-Yi Chao, M.D.||+email@example.com|
|Tri-Service General Hospital||Recruiting|
|Taipei, Neihu, Taiwan, 11490|
|Contact: Tsu-Yi Chao, M.D. +886287927208 firstname.lastname@example.org|
|Principal Investigator: Tsu-Yi Chao, M.D.|
|Principal Investigator:||Tsu-Yi Chao, M.D||Tri-Service General Hospital|